Philipp Haas

Philipp Daniel Haas (born 1960) is an investor, CEO and businessman.

Philipp Haas
Born
Philipp Daniel Haas

1960
Switzerland
NationalitySwiss, New Zealander, Turkish
Alma materM.B.A., University of St.Gallen, St. Gallen, Switzerland
Occupation(s)Investor, CEO
Years active1985-present
Website

Haas is currently Chairman and CEO of Deva Holding A.S., a Turkish pharmaceutical company.[1][2]

Early Years

Philipp Haas was born in July, 1960 in Switzerland.

In 1985 Haas completed a Master of Business Administration (MBA) from the University of St. Gallen.[3]

Current interests

Pharmaceutical Industry

Established in 1958, pharmaceutical manufacturer Deva is a Turkish Fortune 500 company with annual revenue of more than US$250 million and staff of approximately 2,300 across its operations in Turkey, Germany, USA and New Zealand.[4][5][6]

In 2006, Haas founded Eastpharma as part of a take over of Deva Holding and was subsequently elected Chairman of the company that year and CEO in 2008.[7][8]

Banking and Investments

In 1985 Haas began his career in investment banking with First Boston in New York and Credit Suisse First Boston (CSFB) in London and moved on to asset management with Swiss private banks Pictet and Sarasin.[9]

Haas then started his own hedge fund operation focused primarily in emerging markets with clients including George Soros and Sir John Templeton.[10]

References
  1. "Antibiotic Long Distance Run". Fortune Magazine. 19 July 2019. Retrieved 15 September 2019.
  2. "Philipp Haas – Chairman & CEO, DEVA, Turkey". Pharma Boardroom Magazine. 29 November 2018. Retrieved 15 September 2019.
  3. "Philipp Haas CEO of Deva Holding". CEO Today Magazine. 31 December 2018. Retrieved 15 September 2019.
  4. "Antibiotic Long Distance Run". Fortune Magazine. 19 July 2019. Retrieved 15 September 2019.
  5. "5 Minutes Interview with: Philipp Haas - Deva". Pharma Horizon Magazine. 4 May 2017. Retrieved 15 September 2019.
  6. "Philipp Haas – Chairman & CEO, DEVA, Turkey". Pharma Boardroom Magazine. 29 November 2018. Retrieved 15 September 2019.
  7. "Capital 500 - Turkey's 500 Largest Companies". Capital Magazine. 31 December 2018. Retrieved 15 September 2019.
  8. "Angles on Pharma". The Business Year. Retrieved 15 September 2019.
  9. "The Hedgeweek Interview: Petek Kutucuoglu, head of research, GEM Global Equities Management: "Timeliness is fundamental"". Hedgeweek. 15 December 2006. Retrieved 30 September 2019.
  10. "The Hedgeweek Interview: Petek Kutucuoglu, head of research, GEM Global Equities Management: "Timeliness is fundamental"". Hedgeweek. 15 December 2006. Retrieved 30 September 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.